Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand.
The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells.
Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter
Monomer. Interacts with ERCC6 (PubMed:26030138). Interacts with TPRN; TPRN interacts with a number of DNA damage response proteins, is recruited to sites of DNA damage and may play a role in DNA damage repair (PubMed:23213405)
(Microbial infection) Interacts with SV40 Large T antigen; this interactions allows viral DNA replication
Endothelial cells
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to TOP1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 67
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT00410358 | Advanced Solid Tumors | A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor. | PHASE1 | COMPLETED |
| NCT04736472 | Gastrointestinal Cancer | Implementing Pharmacogenetic Testing in Gastrointestinal Cancers | NA | COMPLETED |
| NCT06619236 | Platinum-resistant Ovarian Cancer | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | PHASE3 | ACTIVE_NOT_RECRUITING |
| NCT01876446 | Recurrent Small Cell Lung Carcinoma | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | PHASE2 | COMPLETED |
| NCT05579366 | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | PHASE1, PHASE2 | RECRUITING |
| NCT00001333 | Leukemia, Lymphoma, Meningeal Neoplasms | Phase I Study of Intrathecal Topotecan | PHASE1 | COMPLETED |
| NCT06710132 | Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | PHASE1, PHASE2 | RECRUITING |
| NCT04514497 | Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT01748019 | Solid Tumors | ST1968 Intravenous (Weekly) in Solid Tumors | PHASE1 | COMPLETED |
| NCT00002933 | Colorectal Cancer | Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | PHASE2 | COMPLETED |